After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
DAWN belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Day One Biopharmaceuticals Inc is $873.77M. A total of 2.08 million shares were traded on the day, compared to an average of 2.16M shares.
In the most recent transaction, Dubow Adam sold 4,319 shares of DAWN for 8.91 per share on Nov 17 ’25. After the transaction, the Gen Counsel & Secretary now owns 62,626 company shares. In a previous transaction on Nov 17 ’25, York Charles N II sold 4,062 shares at 8.91 per share. DAWN shares that COO and CFO owns now total 294,715.
Among the insiders who sold shares, Merendino Lauren disposed of 3,726 shares on Nov 17 ’25 at a per-share price of $8.91. This resulted in the Chief Commercial Officer holding 50,809 shares of DAWN after the transaction. In another insider transaction, Bender Jeremy sold 15,894 shares at $8.91 per share on Nov 17 ’25. Company shares held by the CHIEF EXECUTIVE OFFICER now total 177,165.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, DAWN has a high of $13.53 and a low of $5.64.
As of this writing, DAWN has an earnings estimate of -$0.2 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.11 per share and a lower estimate of -$0.36. The company reported an EPS of -$0.63 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. DAWN’s latest balance sheet shows that the firm has $284.31M in Cash & Short Term Investments as of fiscal 2021. There were $220.00k in debt and $8.66M in liabilities at the time. Its Book Value Per Share was $4.39, while its Total Shareholder’s Equity was $281.15M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DAWN is Buy with a score of 4.50.
